Hyderabad-based Natco Pharma Ltd. has been awarded a favourable judgment in the US Court of Appeals for the Federal Circuit ruling on patent-related to Teva’s Copaxone (treat multiple sclerosis). The court of appeals had reversed a district court’s finding related to Copaxone patent.

“This would essentially mean that Natco could launch the generic version of Copaxone through its marketing partner Mylan Inc during May 2014 subject to FDA approval,” the company said in a release.